Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-20
1996-11-26
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546171, C07D40312, A61H 3147
Patent
active
055786073
ABSTRACT:
The subject invention relates to compounds having the structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4029792 (1977-06-01), Danielewicz et al.
patent: 4036976 (1977-07-01), Neumann
patent: 4217356 (1980-08-01), Neumann
patent: 4398028 (1983-08-01), Neumann
patent: 5021416 (1991-06-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
patent: 5180721 (1993-01-01), Burke
patent: 5231096 (1993-07-01), Gluchowski et al.
patent: 5281591 (1994-01-01), Burke
Cambridge, D., "UK-14,304, A Potent and Selective .alpha..sub.2 -Agonist for the Characterization of .alpha.-Adrenoceptor Subtype", European Journal of Pharmacology, vol. 72, pp. 413-415 (1981).
Chapleo, C. B., J. C. Doxey, P. L. Myers, M. Myers, C. F. C. Smith and M. R. Stillings "Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of some Standard .alpha.-Adrenoreceptor Agents", European Journal of Medicinal Chemistry, vol. 24, pp. 619-622 (1989).
Chapleo, C. B., R. C. M. Butler, D. C. England, P. L. Myers, A. G. Roach, C. F. C. Smith, M. R. Stillings and I. F. Tulloch, "Heteroaromatic Analogues of the .alpha..sub.2 -Adrenoreceptor Partial Agonist Clondine", J. Med. Chem., vol. 32, pp. 1627-1630 (1989).
Clare, K. A., M. C. Scrutton and N. T. Thompson, "Effects of .alpha..sub.2 -Adrenoreceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclose Activity in, Human Platelets", Br. J. Pharmacl, vol. 82, pp. 467-476 (1984).
Timmermans, P. B. M. W. M. and P. A. van Zwieten, ".alpha..sub.2 -Adrenoceptor Agonists and Antagonists", Drugs of the Future, vol., 9, No. 1, pp. 41-55 (Jan., 1984).
Timmermans, P. B. M. W. M. A. T. Chiu and M. J. M. C. Thoolen, "12,1.alpha..sub.2 -Adrenergic Receptors", Comprehensive Medicinal Chemistry, vol. 3, Membranes & Receptors, pp. 133-185 (1990).
Timmermans, P. B. M. W. M. A. de Jonge, M. J. M. C. Thoolen, B. Wilffert, H. Batink and P. A. van Zwieten, "Quantitative Relationships between .alpha..sub.2 -Adrenergic Activity and Binding Affinity of .alpha..sub.2 -Adrenoceptor Agonists and Antagonists", J. Med. Chem., vol. 27, pp. 495-503 (1984).
Megens, A. A. H. P., J. E. Leysen, F. H. L. Awouters and C. J. E. Niemegeers, "Ruther Validation of In Vivo and In Vitro Pharmacological Procedures for Assessing the .alpha..sub.2 /.alpha..sub.1 -Selectivity of Test Compounds: (2) .alpha.-Adrenoceptor Agonists", European Journal of Pharmacology, vol. 129, pp. 57-64 (1986).
Van Meel, J. C. A., A. de Jonge, P. B. M. W. M. Timmermans and P. A. van Zwieten, "Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, pp. 760-767 (1981).
Zinchenko, T. M., "Investigation of Autollergenic Action of Dibutyl and Dioctyl Phthalates", Gig. Sanit., vol. 1, pp. 79-80.
Ares Jeffrey J.
Cupps Thomas L.
Maurer Peter J.
Clark Karen F.
Hake Richard A.
McMahon Mary Pat
Springer David B.
The Procter & Gamble & Company
LandOfFree
6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1973409